🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 18 of 55

  1. Dexamethasone 4 mg tablets, Cytarabine 20 mg/ml Solution for Injection or Infusion, Calquence 100 mg hard capsules, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Histergan Tablets, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, Mesna Injection, Methylprednisolone 1000 mg powder and solvent for solution for injection/infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Panadol 50

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  2. Dietary

    The University of Hong Kong

    Colorectal Cancer

    phase 2 other active

    1 trial

  3. Disitamab Vedotin

    Pfizer Australia Pty Ltd

    HER2 Expressing Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  4. Disitamab Vedotin

    The First People's Hospital of Lianyungang

    HER2-positive Gastric Cancer

    phase 2 small molecule active

    1 trial

  5. Disitamab Vedotin (RC48)

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  6. Docetaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Prostatic Neoplasms

    phase 2 small molecule completed

    1 trial

  7. Docetaxel

    Karyopharm Therapeutics Inc

    Recurrent Squamous Cell Lung Carcinoma

    phase 2 small molecule terminated

    1 trial

  8. Docetaxel

    Hospital Authority, Hong Kong

    Non Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  9. Docetaxel

    Takeda

    Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  10. Docetaxel

    Merck KGaA, Darmstadt, Germany

    Castration-Resistant Prostatic Cancer

    phase 2 small molecule active

    1 trial

  11. Docetaxel + Sunitinib

    Samsung Bioepis NL B.V.

    Advanced Gastric Cancer

    phase 2 small molecule completed

    1 trial

  12. Docetaxel, Reolysin and Prednisone

    ONCOLYTICS BIOTECH INC

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  13. Dociparstat sodium

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  14. Domvanalimab

    Arcus Biosciences

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    2 trials

  15. Domvanalimab

    Arcus Biosciences

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Domvanalimab

    Arcus Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  17. Donafenib + Envafolimab

    Anhui Provincial Hospital

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  18. Dopacis 90 MBq/ml oplossing voor injectie

    CERO THERAPEUTICS HOLDINGS, INC.

    patients with newly discovered brain metastases (non-small cell lung cancer, breast cancer or melanoma) measuring more than 5 mm and explored on MRI

    phase 2 small molecule active

    1 trial

  19. Dordaviprone (ONC201)

    Jazz Pharmaceuticals Ireland Limited

    Endometrial Cancer Recurrent

    phase 2 small molecule terminated

    1 trial

  20. Dose Escalation Doublet: Combination of NKTR-214 + nivolumab

    Nektar Therapeutics UK Limited

    Melanoma

    phase 2 small molecule completed

    1 trial

  21. Dostarlimab

    LIXTE BIOTECHNOLOGY HOLDINGS, INC.

    Ovarian Clear Cell Carcinoma

    phase 2 small molecule active

    1 trial

  22. Doxorubicin Hydrochloride

    Children's Hospital of Fudan University

    Childhood Renal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  23. Doxorubicin liposome

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  24. Doxycycline

    United Therapeutics Europe Ltd

    Advanced Malignant Neoplasm

    phase 2 small molecule completed

    1 trial

  25. Dragon Boat Training

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  26. Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank

    BRIGHT MINDS BIOSCIENCES INC.

    Previously Treated Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  27. Drug: B10 L-BPA Injection

    Heron Therapeutics

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  28. Drug: GC4419

    Galera Therapeutics

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  29. Drug: Pembrolizumab

    Hospital Authority, Hong Kong

    Clear-cell Metastatic Renal Cell Carcinoma

    phase 2 other active

    1 trial

  30. Dupilumab

    Regeneron UK Limited

    Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  31. Dupilumab

    Coherus Oncology

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  32. Durvalumab

    United Therapeutics Europe Ltd

    Stage IB Hepatocellular Carcinoma AJCC v8

    phase 2 mab active

    1 trial

  33. Durvalumab

    Syndax Pharmaceuticals

    Unresectable Intrahepatic Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  34. Durvalumab + Oleclumab

    MedImmune

    Stage III Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  35. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    HPV-Associated Cervical Carcinoma

    phase 2 mab active

    1 trial

  36. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    Cervical Cancer

    phase 2 mab active

    1 trial

  37. E7080

    Eisai Co.,

    Solid Tumors

    phase 2 small molecule completed

    1 trial

  38. E7090

    Eisai Co.,

    Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  39. E7386, Doxorubicin EBEWE 2 mg/ml koncentratas infuziniam tirpalui, E7386, Паклитаксел Ебеве 6 mg/ml концентрат за инфузионен разтвор, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Doxorubicina Aurobindo 2 mg/ml concentrato per soluzione per infusione, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules

    Eisai Co.,

    Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor

    phase 2 small molecule active

    1 trial

  40. EBV-TCR-T (YT-E001) cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 mab active

    1 trial

  41. EBV-specific T cells (EBV-CTLs)

    Evidence Based Cataract Study Group

    EBV-induced Lymphomas

    phase 2 mab completed

    1 trial

  42. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  43. EG-70 (phase 1)

    Shanghai Antengene Corporation Limited

    Superficial Bladder Cancer

    phase 2 small molecule active

    1 trial

  44. EGF816, EGF816, LEE011, LEE011

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 2 small molecule active

    1 trial

  45. EGFR-TK Inhibitor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nonsmall Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  46. EIK1003 5mg Tablets, PREDNISONE , ABIRATERONE , EIK1003 20mg Tablets, PACLITAXEL

    Eikon Therapeutics

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  47. EIK1004 20mg Tablets, EIK1004 5mg Tablets

    Eikon Therapeutics

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  48. EIK1004-001 (IMP1707-001)

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.